Table 4.
Seropositivity of GPCR-AAbs in local and systemic disorders.
| α1-AAb | β1-AAb | β2-AAb | M2-AAb | AT1-AAb | ETA-AAb | Noci-AAb | MAS-AAb | Reference | |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer’s disease | x | x | [71] | ||||||
| Vascular dementia | x | x | x | [71] | |||||
| Chagas’ disease | x | x | x | [27,72] | |||||
| DCM | x | x | [27] | ||||||
| Preeclampsia | x | [28] | |||||||
| Hypertension | x | x | [45] | ||||||
| Myocarditis | x | [68] | |||||||
| Glaucoma | x | [25] | |||||||
| Post COVID | x | x | x | x | x | x | x | [13] | |
| CFS | x | [26] | |||||||
| POTS | x | x | x | x | x | [50,51] | |||
| TAO | x | x | x | [73] | |||||
| Type 2 diabetes | x | x | x | [74] | |||||
| Allergic Asthma | x | [75] | |||||||
| After Chemotherapy | x | x | x | [48] |
DCM = dilated cardiomyopathy; TAO = thromboangitis obliterans; POTS = postural orthostatic tachycardia syndrome; CFS = chronic fatigue syndrome; α1-AAb = autoantibody targeting α1-adrenergic receptor; β1-AAb = autoantibody targeting β1-adrenergic receptor; β2-AAb = autoantibody targeting β2-adrenergic receptor; M2-AAb = autoantibody targeting muscarinic-M2 receptor; AT1-AAb = autoantibody targeting angiotensin-II-AT1 receptor; ETA-AAb = autoantibody targeting endothelin-A receptor; Noci-AAb = autoantibody targeting nociceptin-like opioid receptor.